MXC: $0.065
What We Change

Holding unique IP, MGC Pharmaceuticals’ Innovation division puts the Company at the forefront of exploration and development into indications that will serve large global markets.

Having recently attained interim GMP Certification at our European facility, MGC Pharma has commenced the full-scale commercial production of CannEpilTM and will soon start clinical studies in epilepsy, based in Slovenia, in addition to ongoing advancement of supplement and nutraceutical products. MGC also hopes to offer patients in Australia with these products and generate revenue from API sales.

Research and Development
  • Longstanding clinical studies in Neurological disorders with Pro Uri Kramer and Dr. David Neubauer
  • Large pool of clinical data via management and advisory expertise
  • Unique patient care with Medical Cannabis
Our cultivation sites
MGC Pharma is actively securing multiple cultivation sites to support an efficient and cost effective supply chain across key global markets.
Our strategic focus is in three major geographical areas of engagement: Europe, North America and Australasia
Business Development

Innovation Division: Having recently attained interim GMP Certification at our European facility, we can soon commence clinical studies in epilepsy, based in Slovenia.

Alongside these trials, we will also continue to work on the development of nutraceuticals and supplement products.

We also hope to make progress on providing patients in the Australian market with these products, as well as generate revenue from API sales.

Projects
  • GMP Cleanroom Manufacturing
  • Active Analytical Laboratories operational
  • Sales and Production of the API worldwide
Partners

Lenis: MGC Pharmaceuticals Ltd has signed a 5-year, Supply and Distribution Agreement with European pharmaceutical distribution company, Lenis farmacevtika d.o.o. (Lenis).

Epilepsy Action Australia: MGC Pharmaceuticals Ltd has signed a collaboration agreement with Australia’s leading Epilepsy association on future joint clinical trials.

HL Pharma: MGC Pharmaceuticals Ltd Australian Supply and Distribution company.

view all partners